Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23389580 | 0.86 | CCR1 (0.39) | ERN1HTTCYP1A2CYP2C19LMNA | |
| SCHEMBL12850536 | 0.82 | HTT (0.38) | HTTCYP1A2CYP2C19PABPC1PIK3R1 | |
| SCHEMBL20810399 | 0.79 | HTT (0.40) | HTTCYP1A2CYP2C19PABPC1PIK3R1 | |
| SCHEMBL14273338 | 0.79 | TDP1 (0.46) | ERN1CYP1A2LMNAMAPTALDH1A1 | |
| SCHEMBL12928104 | 0.79 | CCR1 (0.35) | PIM1ALDH1A1 | |
| SCHEMBL2621768 | 0.78 | HTT (0.36) | HTTCYP1A2CYP2C19PABPC1PIK3R1 | |
| SCHEMBL2016701 | 0.76 | BACE1 (0.52) | ERN1HTTCYP1A2CYP2C19PABPC1 | |
| SCHEMBL18614453 | 0.75 | PABPC1 (0.41) | HTTCYP1A2CYP2C19PABPC1PIK3R1 | |
| SCHEMBL26919701 | 0.75 | HTT (0.44) | HTTCYP1A2CYP2C19PABPC1PIK3R1 | |
| SCHEMBL97699 | 0.75 | ALDH1A1 (0.47) | ERN1HTTPIM1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119119033-A | Pyrazolopyridone compounds | 百济神州有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240300951-A1 | Pyrazolopyridinone Compounds | BEIGENE LTD. (KY) | 2024-09-12 | — | — | US | disclosed |
| US-20240270751-A1 | Pyrazolopyridinone Compounds | BEIGENE LTD. (KY) | 2024-08-15 | — | — | US | disclosed |
| EP-4380936-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | BeiGene, Ltd. (KY) | 2024-06-12 | — | — | EP | disclosed |
| CN-117836296-A | Pyrazolopyridone compounds | 百济神州有限公司 | 2024-04-05 | — | — | CN | disclosed |
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| WO-2023011456-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | BEIGENE, LTD. (KY) | 2023-02-09 | — | — | WO | disclosed |
| EP-2916838-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA INC (US) | 2019-03-13 | — | — | EP | disclosed |
| EP-2916838-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA INC (US) | 2019-03-13 | — | — | EP | disclosed |
| US-20150030588-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC | 2015-01-29 | — | — | US | disclosed |
| US-20150030588-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC | 2015-01-29 | — | — | US | disclosed |
| WO-2014151147-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE, LLC (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014075077-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2014-05-15 | — | — | WO | disclosed |
| WO-2014075077-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2014-05-15 | — | — | WO | disclosed |
| US-20130035324-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2013-02-07 | — | — | US | disclosed |
| US-20130035324-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2013-02-07 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012116237-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2012-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | ERN1 602/4885HTT 683/4885CYP1A2 1496/4885 |
| US-20150030588-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | PIK3C3, ERBB3, ERBB2 | ERN1 710/4885HTT 2157/4885CYP1A2 4739/4885 |
| US-20130035324-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | ERN1 602/4885HTT 683/4885CYP1A2 1496/4885 |
| US-20240300951-A1 | Pyrazolopyridinone Compounds | NFATC1, CD4, PBK | ERN1 3400/4885HTT 4803/4885CYP1A2 2016/4885 |
| US-20240270751-A1 | Pyrazolopyridinone Compounds | NFATC1, CD4, PBK | ERN1 3400/4885HTT 4803/4885CYP1A2 2016/4885 |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | MTOR, AKT2, MTMR1 | ERN1 485/4885HTT 985/4885CYP1A2 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.